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Abstract
Background: Following the successful introduction of five topic-specific research networks in the UK, the
Comprehensive Local Research Network (CLRN) was established in 2008 in order to provide a blanket level of
support across the whole country regardless of the clinical discipline. The role of the CLRN was to facilitate
recruitment into clinical trials, and to encourage greater engagement in research throughout the National Health
Service (NHS).
Methods: This report evaluates the impact of clinical research networks in supporting clinical trials in the UK, with
particular reference to our experiences from two non-commercial dermatology trials. It covers our experience of
engaging with the CLRN (and other research networks) using two non-commercial dermatology trials as case
studies. We present the circumstances that led to our approach to the research networks for support, and the
impact that this support had on the delivery of these trials.
Results: In both cases, recruitment was boosted considerably following the provision of additional support,
although other factors such as the availability of experienced personnel, and the role of advertising and media
coverage in promoting the trials were also important in translating this additional resource into increased
recruitment.
Conclusions: Recruitment into clinical trials is a complex task that can be influenced by many factors. A world-
class clinical research infrastructure is now in place in England (with similar support available in Scotland and
Wales), and it is the responsibility of the research community to ensure that this unique resource is used effectively
and responsibly.
Background
The last five years have seen an unprecedented increase
in support for the conduct of applied clinical research in
the UK. The changes introduced as a result of the far-
reaching report “Best Research for Best Health”[1],
called for the development of the National Health Ser-
vice (NHS) as a world leader in delivering high-quality
and timely clinical research. Through the development
of the National Institute for Health Research (http://
www.nihr.ac.uk), many changes have now been imple-
mented. Some of the key developments include: the
streamlining of research approval processes; the devel-
opment of a national portfolio of trials to improve
accountability and clarity of trial reporting; and the
establishment of clinical research networks - with the
aim of supporting the delivery of high quality research
within the NHS. Topic specific networks have been cre-
ated in areas of high priority (e.g. stroke, cancer and
mental health), and over-arching networks have been
created to support research across a variety of disci-
plines (the Medicines for Children Research Network -
MCRN; the Primary Care Research Network - PCRN;
and the Comprehensive Local Research Network -
CLRN). The overall objectiveso ft h e s en e t w o r k sa r e :i )
to introduce effective systems to speed up the regulatory
approval process; ii) to provide infrastructure to support
clinical research activities; and iii) to facilitate access to
appropriate patient populations.
This brief paper focuses on the impact that the clinical
research networks have had on delivery of trials con-
ducted in the field of dermatology, using two non-
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Dermatology was well-placed to take advantage of the
newly emerging research infrastructure as it developed,
s i n c et h ed i s c i p l i n ea l r e a d yh a daw e l l - d e v e l o p e dc o l l a -
borative research network in the form of the UK Der-
matology Clinical Trials Network (http://www.ukdctn.
org). This led to dermatology being identified as a prior-
ity area in 18 of the 25 CLRN regions in England, many
of which were able to provide considerable support in
the form of research nurses, trial administrators, and
support for the time of recruiting clinicians.
This paper describes the impact that CLRN, MCRN
and PCRN support had on the completion of two der-
matology trials, and highlights some of the challenges
and lessons that we have learnt as a result. These case
studies are presented in chronological order based on
t h et i m ea tw h i c hs u p p o r tf r o mt h eC l i n i c a lR e s e a r c h
Networks was first accessed.
Methods
Case Study 1: Softened Water Eczema Trial (SWET)
The scenario
The Softened Water Eczema Trial (SWET) was a multi-
centre randomised controlled trial funded by the NIHR
Health Technology Assessment programme (HTA) [2,3].
The study was well-resourced and included funding for
four part-time research nurses and a trial manager.
Recruitment was anticipated to take 18 - 24 months
starting in March 2007. Despite overwhelming support
from patients, recruitment had been slower than antici-
pated due to changes in personnel (one research nurse
left and one went on maternity leave), and a higher than
expected numbers of participants’ homes that were
found to be unsuitable for the installation of a water
softener (the intervention).
The Trial Steering Group decided to focus on four
options to boost recruitment: i) focussing on media
advertising, ii) opening new centres, iii) referring
patients from nearby hospitals, and iv) approaching the
NIHR Clinical Research Networks for support. In Octo-
ber 2008, the Trial Steering Group approved a request
to the funders for a six-month extension to the study, at
an estimated cost of £100,000.
Involvement of NIHR Clinical Research Network
The SWET trial was adopted by the MCRN and added
to the NIHR portfolio of trials in March 2008 [4]. The
MCRN provided maternity leave cover from August
2008 for our London centre (which up until this point
had been our top recruiting site), and allowed us to
open two new recruiting centres in Lincoln (June 2008),
and South East London (December 2008).
In addition, Trent CLRN andH a m p s h i r ea n dI s l eo f
Wight CLRN provided nurse time in Nottingham, and
administrative support in the Isle of Wight. This addi-
tional support meant that the SWET research nurses
were able to open up two new recruiting centres in Lei-
cester and Portsmouth respectively.
We also approached the PCRN, who assisted with the
identification of suitable patients from GP databases in
Cambridge, Isle of Wight and Leicester.
Although the speedy intervention of the research net-
works allowed us to maintain our recruitment rate at a
time when it might otherwise have declined, by far the
most influential event in ensuring that the SWET study
completed recruitment to target was the appearance of
the principal investigator for Portsmouth on the local
BBC TV News. This resulted in a deluge of calls to the
co-ordinating centre (more than 700 contacts over a
period of 2 weeks). Only through the speedy response of
the Trent CLRN in providing administrative support for
the Trial Manager were we able to respond to these
queries, and translate this interest into improved
recruitment.
Overall impact
Through a combination of the measures outlined above,
the recruitment target was reached by June 2009. This
meant that the trial was delivered on budget (after a
short 4 month no-cost extension for analysis and write-
up), and the proposed funding extension of £100,000
was not required.
The dramatic increase in trial recruitment during the
final six months of the trial is illustrated in Figure 1.
Case Study 2: Prophylactic Antibiotics For The Prevention
Of Cellulitis Of The Leg (Patch I Trial)
The scenario
The PATCH study was the first trial to be conducted
through the UK Dermatology Clinical Trials Network,
and was funded by a medical charity (Action Medical
Research). This trial was intended to test the ability of
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Figure 1 Recruitment graph for SWET trial.
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few patients from many centres; thus allowing busy clin-
icians to engage in research in a meaningful way, with-
out over burdening any one site. As a result funding for
the trial was limited to a trial manager and an adminis-
trator at the co-ordinating centre, but no dedicated
research nurses at recruiting sites. Whether such a
model is possible in the current regulatory climate, and
for a condition such as cellulitis, which is often seen by
specialties other than dermatology, is unclear. Subse-
quent UK DCTN trials of rare skin conditions that are
being treated by dermatologists are proving more suc-
cessful in this regard (http://www.ukdctn.org).
Recruitment was anticipated to take 12 months from
April 2006 to April 2007. However, by Dec 2007,
recruitment was just 62 (24%) of target and we were
faced with having to close the trial early due to lack of
funding. Indeed, a related trial (PATCH II) was closed
at this time [5].
At the time of approaching the NIHR CRN, recruit-
ment into the PATCH trial was hampered by three key
factors: i) the absence of trial staff at each of the 29
recruiting centres meant that all trial related administra-
tive tasks were devolved to the recruiting clinician, mak-
i n gi tv e r yt i m ec o n s u m i n gf o rb u s yc l i n i c i a n s ;i i )
because cellulitis is an acute inflammation of the skin
and underlying tissue, patients were generally treated in
emergency care settings, rather than on a dermatology
wards or outpatients setting. This made it difficult, and
time-consuming for our network of volunteer dermatol-
ogists to identify and recruit suitable patients; iii)
because recruitment during the early phases of the trial
h a db e e ns l o w ,t h es u p p l yo ft r i a ld r u g sw a sd u et o
expire, and funds were not available from the funder to
buy further supplies, potentially halting recruitment if
alternative arrangements were not found.
Involvement of NIHR CRN
The PATCH study was adopted onto the UK CRN port-
folio of trials in April 2008. All CLRN areas where der-
matology was identified as a priority area were
approached with a view to providing local support at
recruiting sites (either research nurses or trial adminis-
trators) to reduce the burden on the dermatologists. In
total, eight CLRNs provided additional support, ranging
f r o m1d a yaw e e ko fr e s e a r c hn u r s et i m e ,t of u l lt i m e
nurses or administrators.
In addition, the PCRN provided assistance with identi-
fying patients through GP surgeries in one region, and
the Trent CLRN agreed to cover the costs of purchasing
more trial drugs using money that had been ring-fenced
for “unblocking the blocks in pharmacy”.
However, for the PATCH trial (as with the SWET
trial), the biggest boost to recruitment came when we
advertised for patients using local media (radio and
adverts placed in local papers). This approach resulted
in a substantial boost to recruitment (>50% increase in
recruitment rate), but again resulted in a considerable
administrative burden at the co-ordinating centre. All
calls were screened by staff at the co-ordinating centre,
before being referred to the relevant recruiting hospital.
In order to meet this challenge, Trent CLRN provided
funding for a full-time trial administrator.
Overall impact
Once again, it was the combined approach of various
strategies, coupled with an understanding of the impor-
tance of advertising the trial beyond the traditional clini-
cal setting that resulted in a positive outcome for the
PATCH trial. By having increased support at the
recruiting centres, the benefits of a centrally co-ordi-
nated publicity drive were immediately translated into
improved recruitment rates at centres throughout the
UK. The study was closed to recruitment in January
2010, having exceeded its target of 260 participants
(Figure 2).
Both of the trials described in this paper were ongoing
at the time that resources became available through the
NIHR Clinical Research Networks, which meant that
the role of the research networks in these trials was pri-
marily “troubleshooting”. Future trials will work more
collaboratively with the research networks, and will ben-
efit greatly from both the systems and the personnel
that are now in place. This was demonstrated clearly
with another of our dermatology trials that was adopted
onto the UK CRN portfolio more recently (the BEEP
feasibility study - Barrier Enhancement for Eczema Pre-
vention) [6]. In this case, support was available from the
outset from both the CLRN and MCRN, and the trial
quickly recruited in excess of its target in three hospitals
across the region.
Figure 2 Recruitment graph for PATCH I Trial.
Thomas et al. Trials 2011, 12:153
http://www.trialsjournal.com/content/12/1/153
Page 3 of 5Discussion
The introduction of research networks with dedicated
nursing and administrative support for clinical trials has
been a fantastic boost to the delivery of clinical research
within the NHS. Nevertheless, this paper provides a use-
ful forum in which to highlight some of the key con-
cerns that researchers face.
How should success be measured?
As with all new initiatives, it is important to have useful
metrics with which to measure success. To date, one of
the main ways of doing this has been an evaluation of
recruitment rates. Whilst there has been much talk
about the need to recognise the variability of study
design in summarising recruitment rates, it is still not
entirely clear how this is achieved. In the absence of
transparency, it is difficult to interpret summary graphs
that combine epidemiological studies (involving poten-
tially thousands of participants) with RCTs in rare con-
ditions (where recruitment of 1-2 participants per centre
may be happening on a global scale). In addition, future
metrics should include additional important measures
such as recruitment to time/target, completion of fol-
low-up, low attrition rates, and timely publication of
trial findings. These areas are just as important as over-
all trial recruitment if findings are to improve the lives
of patients and inform clinical decision making. In this
regard, we have been particularly helped by the Trent
CLRN, which currently provides support for two derma-
tology trial administrators. These posts not only support
recruitment into our trials, but also play a big role in
ensuring ongoing data collection, participant retention
and trial completion.
Of particular relevance to the Comprehensive Local
Research Networks is the need to ensure that there is
appropriate transparency and accountability across the
different networks. As for many disciplines, dermatology
spans many topic areas and many of our trials involve
collaboration with the Medicines for Children Research
Network (MCRN), the Primary care Research Network
(PCRN), and the Cancer Research Network (CRN), as
well as the generic CLRN. Ensuring that all networks are
adequately recognised in contributing to the success of a
study can be a challenge, and relies upon correct tagging
of the trials as they are entered onto the portfolio. In our
experience, this is an area that can be facilitated by the
close involvement of the relevant Specialty Groups [7], so
that recruitment figures are credited appropriately across
multiple networks. For example, a recent audit of the
portfolio by the Dermatology Specialty Group found four
skin cancer trials that were included in the cancer net-
work’s portfolio but were not in the dermatology portfo-
lio (even when the lead investigator on the trial was a
dermatologist). By writing to all of the relevant
investigators, and in close collaboration with the portfolio
teams at the Clinical Research Network Co-ordinating
Centre, this situation was rectified and recruitment fig-
ures were collected by all relevant networks.
Does the system discourage collaborative, multi-centre
trials?
Given that future funding is tied to current activity by
CLRN region, there is a possibility that investigators will
be tempted to design trials that recruit solely within
their own region in order to secure future infrastructure
support. This has potential to reduce the generalisability
of trial results if participants all come from a very select
population or region.
For an organisation such as the UK Dermatology Clin-
ical Trials Network that specialises in conducting trials
in rare conditions, individual centres may contribute
just one or two participants per year. It is possible that
local Trusts and investigators may find studies of this
kind less appealing than ones that are able to make a
larger contribution to their overall recruitment rates.
Future adoption of trial findings may be impeded if
fewer clinicians have had experience of using and pre-
scribing the newly investigated products [8].
Administration and implementation
As with any new system, it takes time for the new admin-
istrative systems and financial arrangement to be stream-
lined. However, our experiences to date would suggest
that there is still room for improvement in this regard.
For multi-centre trials that require support at a national
level, negotiating local arrangements can be time-consum-
ing and potentially fragmented. Further streamlining of
the application process in line with other regulatory
approvals in order to avoid duplication of effort is
required. Indeed, this is now emerging and all new studies
are assessed for adoption onto the NIHR portfolio at an
early stage, and a designated “lead network” is identified as
part of the application process through the NIHR Coordi-
nated System for gaining NHS Permissions (http://www.
crncc.nihr.ac.uk/about_us/processes/csp). This process
ensures that the needs of studies are evaluated prior to
initiation of the research activity, and negotiations with
other networks are facilitated by experienced network staff
familiar with the process.
In addition, fostering and enhancing shared working
practices between NHS Trusts and the Universities,
where much of the research is planned and managed, is
still a crucial area. It is important that systems created
in order to generate and facilitate high quality research
within the NHS allow for close collaboration between
NHS and University colleagues.
Managing the day-to-day activities of research staff
employed through the CLRN can also be challenging.
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stantly working with different research teams and are
involved in the delivery of multiple trials across the
portfolio. This role can be less satisfying for the indivi-
dual research nurses/administrators as their role is often
seen as being one of “plugging the gaps” rather than as
an integrated and valued member of the research team.
This can lead to high staff turn-over and engagement
with the individual studies could be compromised.
Equally, for managers the role can be difficult and
time-consuming. Responsibility for deciding which stu-
dies are to receive support, allocating tasks, training and
managing the staff, negotiating hours, and planning for
future activity requires a broad understanding of both
research design and the needs of local teams.
Conclusion
The last five years have seen unprecedented support for
clinical research in the UK and one which has trans-
formed the way in which research is designed and
implemented in this country. The additional resource
allocated to the trials highlighted in this report meant
that both studies recruited to target and that two impor-
tant clinical questions can now be addressed. However,
it is clear that simply increasing resources is not suffi-
cient in isolation. Neither of the trials would have bene-
fited from the increased financial support without the
availability of experienced and extremely dedicated
research teams, who strove to ensure that the trials
were of high quality and delivered to target. Success was
driven by a genuine partnership between the research
teams and the flexibility of network support.
For both trials, raised public awareness was key.
Further input into the ways in which members of the
public can be made aware of ongoing trials, as well as
initiatives to improve the public’s understanding of clini-
cal research would be beneficial.
The next challenge for researchers is to find novel and
innovative ways of ensuring that new research is imple-
mented into practice, and to look at ways of building
treatment evaluation into normal clinical practice. This
will be facilitated if the newly evolving structures allow
easy and transparent support across the whole country,
rather than encouraging competition between geogra-
phical regions.
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